HALO

91.3501.82%
GI

Gregory I. Frost

Chairman of Scientific Advisory Board

Dr. Gregory I. Frost, also known as Greg, Ph.D. serves as Chairman and Chief Executive Officer at EXUMA Biotech Corp. (formerly known as F1 Oncology, Inc.). He is an acting advisor to the company's HER2 program. He serves as a Managing Director at F1BioVentures. He served as Senior Vice President of Health Sector at Intrexon Corporation from January 6, 2014 to July 2015. Dr. Frost co-founded Halozyme Therapeutics, Inc. in 1999 served as its Chief Executive Officer and President from December 3, 2010 to January 6, 2014. He served as the Chief Scientific Officer at Halozyme Therapeutics, Inc. from December 2002 to December 3, 2010 its Vice President until December 3, 2010. Mr. Shepard, Ph.D. is known for leading the research team that discovered the antibody therapy Herceptin (trastuzumab). For this work, in 2019, He joined Halozyme in 1999 and has spent more than ten years researching the hyaluronidase family of enzymes. From 1998 to 1999, he served as a Senior Research Scientist at the Sidney Kimmel Cancer Center (SKCC), where he focused much of his work developing the hyaluronidase technology. Prior to SKCC, Dr. Frost's research in the Department of Pathology at the University of California, San Francisco, led directly to the purification, cloning, and characterization of the human hyaluronidase gene family, and the discovery of several metabolic disorders. Dr. Frost's prior experience includes serving as a Scientific Consultant to a number of biopharmaceutical companies, including Q-Med (SE), Biophausia AB (SE), and Active Biotech (SE). He is registered to practice before the US Patent Trademark Office. He has been the Chairman of Scientific Advisory Board at Halozyme Therapeutics, Inc. since January 6, 2014. He served as a Director of Halozyme Therapeutics, Inc. from 1999 to January 6, 2014. He has authored over 13 scientific peer-reviewed and invited articles in the Hyaluronidase field and is an inventor on numerous patents. Dr. Frost earned his B.A. in Biochemistry and Molecular Biology from the University of California, Santa Cruz, and his Ph.D in the department of Pathology at the University of California, San Francisco, where he was an ARCS-Scholar.

Positions